nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation
|
Qayed, Muna |
|
|
6 |
3 |
p. 746-749 |
artikel |
2 |
ABCB6 polymorphisms are not overly represented in patients with porphyria
|
Farrell, Colin P. |
|
|
6 |
3 |
p. 760-766 |
artikel |
3 |
A clinical laboratory–developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemia
|
Ng, Stanley W.K. |
|
|
6 |
3 |
p. 1064-1073 |
artikel |
4 |
Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19
|
Wygrecka, Malgorzata |
|
|
6 |
3 |
p. 1074-1087 |
artikel |
5 |
An engineered activated factor V for the prevention and treatment of acute traumatic coagulopathy and bleeding in mice
|
Joseph, Bilgimol Chumappumkal |
|
|
6 |
3 |
p. 959-969 |
artikel |
6 |
Antithrombin protects against Plasmodium falciparum histidine-rich protein II-mediated inflammation and coagulation
|
Biswas, Indranil |
|
|
6 |
3 |
p. 931-945 |
artikel |
7 |
Antithymocyte globulin exposure in CD34+ T-cell–depleted allogeneic hematopoietic cell transplantation
|
Lakkaraja, Madhavi |
|
|
6 |
3 |
p. 1054-1063 |
artikel |
8 |
ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome
|
West, Robert R. |
|
|
6 |
3 |
p. 793-807 |
artikel |
9 |
Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis
|
Locatelli, Franco |
|
|
6 |
3 |
p. 1004-1014 |
artikel |
10 |
Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19
|
Piñana, José Luis |
|
|
6 |
3 |
p. 848-853 |
artikel |
11 |
C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19
|
Aiello, Sistiana |
|
|
6 |
3 |
p. 866-881 |
artikel |
12 |
Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
|
Jiménez, Moraima |
|
|
6 |
3 |
p. 774-784 |
artikel |
13 |
Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
|
Mohan, Meera |
|
|
6 |
3 |
p. 808-817 |
artikel |
14 |
Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia
|
Kaur, Manraj N. |
|
|
6 |
3 |
p. 785-792 |
artikel |
15 |
Cumulative incidence of subsequent malignancy after allo-HCT conditioned with or without low-dose total body irradiation
|
Nunez, Lina |
|
|
6 |
3 |
p. 767-773 |
artikel |
16 |
Daratumumab for immune thrombotic thrombocytopenic purpura
|
van den Berg, Jana |
|
|
6 |
3 |
p. 993-997 |
artikel |
17 |
Decreased IL-10 accelerates B-cell leukemia/lymphoma in a mouse model of pediatric lymphoid leukemia
|
Fitch, Briana A. |
|
|
6 |
3 |
p. 854-865 |
artikel |
18 |
Editorial Board
|
|
|
|
6 |
3 |
p. i |
artikel |
19 |
Epstein Barr virus–positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo
|
Zhang, Xiaoshan |
|
|
6 |
3 |
p. 891-901 |
artikel |
20 |
Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study
|
Böttcher, Sebastian |
|
|
6 |
3 |
p. 976-992 |
artikel |
21 |
GRNDaD: big data and sickle cell disease
|
Lanzkron, Sophie |
|
|
6 |
3 |
p. 1088 |
artikel |
22 |
Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry
|
Jones, David A. |
|
|
6 |
3 |
p. 909-919 |
artikel |
23 |
LNK (SH2B3) inhibition expands healthy and Fanconi anemia human hematopoietic stem and progenitor cells
|
Holdreith, Nicholas |
|
|
6 |
3 |
p. 731-745 |
artikel |
24 |
Morbidities and mortality in patients with hereditary thrombotic thrombocytopenic purpura
|
Borogovac, Azra |
|
|
6 |
3 |
p. 750-759 |
artikel |
25 |
Multifaceted pathomolecular mechanism of a VWF large deletion involved in the pathogenesis of severe VWD
|
Yadegari, Hamideh |
|
|
6 |
3 |
p. 1038-1053 |
artikel |
26 |
Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors
|
Schweiger, Helmut |
|
|
6 |
3 |
p. 946-958 |
artikel |
27 |
Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics
|
Hamadani, Mehdi |
|
|
6 |
3 |
p. 920-930 |
artikel |
28 |
Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma
|
Bröske, Ann-Marie E. |
|
|
6 |
3 |
p. 1025-1037 |
artikel |
29 |
Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1
|
Oñate, Guadalupe |
|
|
6 |
3 |
p. 882-890 |
artikel |
30 |
Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study
|
Van Der Valk, Paul |
|
|
6 |
3 |
p. 902-908 |
artikel |
31 |
Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy
|
Castillo, Jorge J. |
|
|
6 |
3 |
p. 1015-1024 |
artikel |
32 |
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
|
Menghrajani, Kamal |
|
|
6 |
3 |
p. 828-847 |
artikel |
33 |
Sequential different B-cell antigen–targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma
|
Liu, Ying |
|
|
6 |
3 |
p. 717-730 |
artikel |
34 |
Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience
|
Diarra, Ava |
|
|
6 |
3 |
p. 998-1003 |
artikel |
35 |
t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity
|
Mueller, Sarah B. |
|
|
6 |
3 |
p. 818-827 |
artikel |
36 |
Vemurafenib acts as a molecular on-off switch governing systemic inflammation in Langerhans cell histiocytosis
|
Eder, Sebastian K. |
|
|
6 |
3 |
p. 970-975 |
artikel |